Price
No data yet.
Social Signal Score
Revenue
$0.00Company Profile
- CEO
- Thomas A. Smeenk
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 488
- Beta
- 0.61
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -454.32
Financials
Net Income
$-612.3KEBITDA
$-586.4KFree Cash Flow
$-368.8KEPS (diluted)
$-0.00Shares Outstanding (diluted)
204.99M+5972.1%Operating Expenses
$475.7KCash & Debt
$196.5KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-4.71M | $-0.03 |
| 2024 | $0.00 | $-2.62M | $-0.03 |
| 2023 | $0.00 | $-2.50M | $-0.03 |
| 2022 | $0.00 | $-5.24M | $-0.07 |
| 2021 | $0.00 | $-6.29M | $-0.11 |
| 2020 | $0.00 | $-7.77M | $-0.24 |
| 2019 | $0.00 | $-4.87M | $-0.32 |
| 2018 | $0.00 | $-6.19M | $-0.41 |
| 2017 | $0.00 | $-3.94M | $-0.56 |
| 2016 | $0.00 | $-3.79M | $-1.12 |
| 2015 | $0.00 | $-3.98M | $-1.13 |
| 2014 | $0.00 | $-4.33M | $-1.39 |
| 2013 | $0.00 | $-1.54M | $-0.50 |
Valuation
HMTXFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-9.09%Social Signal Score
Mentions (4)
- Newsnewsfilecorp.com·7d ago·Neutral
Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit Calgary, Alberta--(Newsfile Corp. - September 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that it is presenting at the Centurion One Capital 4th Annual Bahamas Summit at Rosewood Baha Mar in Nassau, The Bahamas, October 19 to October 21, 2026. The invitation-only summit brings together company executives, institutional investors and family offices f…
View source ↗ - Newsnewsfilecorp.com·12d ago·Negative
Hemostemix Non Brokered Private Placement Calgary, Alberta--(Newsfile Corp. - September 23, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is filing a Form 4B to obtain price protection for the closing of the third tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026, to raise $1,000,000. Each Unit consists of one common share in the capital …
View source ↗ - Newsnewsfilecorp.com·46d ago·Neutral
…EST, at https://us06web.zoom.us/webinar/register/WN_nJ8ViLkRSeiU_NXMYJ-jbw Calgary, Alberta--(Newsfile Corp. - August 20, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce > 130 participants have enrolled to hear Dr. William R. Shankle, MS, MD, FACP, special presentation entitled: "Vascular Cognitive Impairment and Vascular Dementia: Recognizing the Vascular Cause and Exploring the Clinical-Trial Application of VesCell™".
View source ↗ - Newsnewsfilecorp.com·55d ago·Positive
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI, as Principal Investigator of Hemostemix' VesCell™ (ACP-01) longevity clinical trial.
View source ↗
Earnings
Fri, Nov 27(in 7 weeks)
Estimates and results for HMTXF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in HMTXF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.